ArticleBlood cancer journal2018

CD26 is a potential therapeutic target by humanized monoclonal antibody for the treatment of multiple myeloma.

Hiroko Nishida et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.